DK2846836T3 - Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi - Google Patents

Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi Download PDF

Info

Publication number
DK2846836T3
DK2846836T3 DK13723356T DK13723356T DK2846836T3 DK 2846836 T3 DK2846836 T3 DK 2846836T3 DK 13723356 T DK13723356 T DK 13723356T DK 13723356 T DK13723356 T DK 13723356T DK 2846836 T3 DK2846836 T3 DK 2846836T3
Authority
DK
Denmark
Prior art keywords
refrachrant
amd
patients
procedure
treatment
Prior art date
Application number
DK13723356T
Other languages
English (en)
Inventor
Thomas C Hohman
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2846836T3 publication Critical patent/DK2846836T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13723356T 2012-05-07 2013-05-06 Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi DK2846836T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261643878P 2012-05-07 2012-05-07
US201261728017P 2012-11-19 2012-11-19
US201261731238P 2012-11-29 2012-11-29
PCT/US2013/039619 WO2013169614A1 (en) 2012-05-07 2013-05-06 Method of treating amd in patients refractory to anti-vegf therapy

Publications (1)

Publication Number Publication Date
DK2846836T3 true DK2846836T3 (da) 2019-11-11

Family

ID=48446670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13723356T DK2846836T3 (da) 2012-05-07 2013-05-06 Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi

Country Status (10)

Country Link
US (3) US10568934B2 (da)
EP (2) EP2846836B1 (da)
AR (1) AR090972A1 (da)
DK (1) DK2846836T3 (da)
ES (1) ES2753135T3 (da)
HU (1) HUE046134T2 (da)
PL (1) PL2846836T3 (da)
PT (1) PT2846836T (da)
TW (1) TW201350128A (da)
WO (1) WO2013169614A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP2846836B1 (en) * 2012-05-07 2019-08-14 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
WO2014124487A1 (en) * 2013-02-18 2014-08-21 Vegenics Pty Limited Ligand binding molecules and uses thereof
CA2927012A1 (en) * 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3278810A4 (en) 2015-03-31 2018-11-21 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
EP3471780B1 (en) * 2016-06-16 2020-10-28 Adverum Biotechnologies, Inc. Treatment of amd using aav2 variant with aflibercept
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45721E1 (en) 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
US5932440A (en) 1996-08-16 1999-08-03 Life Technologies, Inc. Mammalian ribonuclease inhibitors and use thereof
US5827692A (en) 1997-04-24 1998-10-27 Heska Corporation Dirofilaria and Brugia ankyrin proteins, nucleic acid molecules, and uses thereof
JP2001510166A (ja) 1997-07-18 2001-07-31 エール ユニヴァーシティ α−Ｎａ、Ｋ−ＡＴＰａｓｅのアンキリン結合ドメインの構造
ES2329959T5 (es) 1998-12-10 2013-12-18 Bristol-Myers Squibb Company Armazones de proteína para miméticos de anticuerpo y otras proteínas de unión
NZ515913A (en) 1999-06-08 2004-01-30 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US20020042094A1 (en) 1999-12-15 2002-04-11 Venezia Domenick R. RING finger protein zapop2
WO2001061005A2 (en) 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
US20020035739A1 (en) 2000-05-05 2002-03-21 Michael Lassner Evolution of plant disease response plant pathways to enable the development of based biological sensors and to develop novel disease resistance strategies
US6750057B2 (en) 2000-06-29 2004-06-15 University Of Florida Ubiquitin ligase
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
WO2006137938A2 (en) 2004-11-08 2006-12-28 The University Of Texas At Austin Antibody fragments for protection from pathogen infection and methods of use thereof
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
EP2263088A2 (en) 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
BR122020011428B1 (pt) 2010-11-26 2023-05-16 Molecular Partners Ag Proteína de ligação que compreende um domínio de repetição de anquirina e composição farmacêutica
EP2846836B1 (en) 2012-05-07 2019-08-14 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
JP2015522576A (ja) 2012-06-28 2015-08-06 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血小板由来成長因子に結合する設計アンキリンリピートタンパク質
CA2927012A1 (en) 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin

Also Published As

Publication number Publication date
ES2753135T3 (es) 2020-04-07
PL2846836T3 (pl) 2020-01-31
TW201350128A (zh) 2013-12-16
US10568934B2 (en) 2020-02-25
EP2846836B1 (en) 2019-08-14
WO2013169614A1 (en) 2013-11-14
EP3646880A1 (en) 2020-05-06
US20220096596A1 (en) 2022-03-31
PT2846836T (pt) 2019-10-29
US20200405808A1 (en) 2020-12-31
AR090972A1 (es) 2014-12-17
EP2846836A1 (en) 2015-03-18
US20130296238A1 (en) 2013-11-07
HUE046134T2 (hu) 2020-02-28

Similar Documents

Publication Publication Date Title
DK2846836T3 (da) Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
LTC2822953I2 (lt) Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3421042T3 (da) Indånding af nitrogenoxid til behandling af luftvejssygdomme
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK2897536T3 (da) Apparat til behandling af vaskulære okklusioner
DK2885010T3 (da) Fremgangsmåder til behandling med tauopati
DK2895621T3 (da) Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
DK3501549T3 (da) Behandling af amd med aav sflt-1
DK2707029T3 (da) Fremgangsmåder til at behandle eller forebygge kolesterolrelaterede sygdomme
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3473278T3 (da) Fremgangsmåde til enzymatisk behandling af vævsprodukter
FI20125146A (fi) Selluloosamassan esikäsittelymenetelmä
DK2861584T3 (da) Pyridopyrazin- og naphthyridinderivater til behandling af cancer
DK2844279T3 (da) Doseringsprogrammer til behandling af pompes sygdom
DK2717692T3 (da) Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme
DK2818241T3 (da) Fremgangsmåde til fremstilling af behandlingsapparat udstyret med katalysatorbærende honeycombstruktur
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK2914310T3 (da) Medicinske indretninger med coatings til forbedret ekkogenicitet
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme